ArticleInternational journal of pharmaceutics: X2025
Electrospun hydrogel-forming nanofibres embedded in a pH-responsive film for the prevention of sexually transmitted infections.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sexually transmitted infections (STIs) remain a major global health challenge, highlighting the urgent need for effective and user-friendly vaginal prevention strategies. This study presents a novel composite system for vaginal application, consisting of mucoadhesive electrospun nanofibres with inherent antiviral potential embedded within a pH-responsive film. The film is designed to preserve the integrity of the nanofibres in the acidic vaginal environment and to dissolve rapidly upon contact with seminal fluid - released during sexual intercourse -, triggering nanofibre hydration and interaction with the mucosal surface. Electrospinning successfully produced uniform and defect-free nanofibres consisting of polyvinyl alcohol (PVA) blended with either κ- or ι-carrageenans (CAR), sulphated polysaccharides known for their mucoadhesive, gelling and intrinsic antiviral properties. Different solutions containing Eudragit® polymers (EL100 or EL100-55) and plasticisers (polyethylene glycol or glycerol) were prepared and cast to identify the most suitable composition for developing the composite system. Solutions capable of forming films with optimal mechanical flexibility and rapid solubility under mildly alkaline conditions were selected. The composite system was fabricated by embedding nanofibres between two partially dried layers of the selected pH-responsive solutions, forming a uniform composite structure that ensured complete fibre incorporation. The outer film effectively protected the nanofibrous core in acidic environments; upon pH increase (pH ∼7.5), the film rapidly dissolved, allowing the nanofibres to hydrate and form a cohesive, strongly mucoadhesive hydrogel, potentially enhancing their retention within the vaginal cavity. Overall, the composite system exhibited good structural integrity, pH-responsiveness, biocompatibility and antiviral potential, offering a promising, non-hormonal strategy for on-demand STI prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.